Theravance/Astellas Antibiotic Telavancin “Approvable” At FDA

Complete response to agency will not require additional trials, but may include revising label, re-analysis of data, Theravance CEO says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet